Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Delcath Systems, Inc. - Common Stock (NQ:DCTH)

11.59 -0.10 (-0.86%)
Streaming Delayed Price Updated: 1:08 PM EDT, Jun 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Delcath Systems, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Delcath Systems Announces Update to National Comprehensive Cancer Network Clinical Practice Guidelines for the Treatment of Metastatic Uveal Melanoma
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
From Delcath Systems, Inc.
Via Business Wire
News headline image
Analyst Expectations For Delcath Systems's Future ↗
 
Via Benzinga
News headline image
Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results
From Delcath Systems, Inc.
Via Business Wire
News headline image
Uncovering Potential: Delcath Systems's Earnings Preview ↗
 
Via Benzinga
News headline image
Analyst Scoreboard: 4 Ratings For Delcath Systems ↗
 
Via Benzinga
News headline image
Assessing Delcath Systems: Insights From 4 Financial Analysts ↗
 
Via Benzinga
News headline image
Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems Announces Additional $16.3 Million in Funding From Series E and E1 Warrant Exercises
From Delcath Systems, Inc.
Via Business Wire
News headline image
MicroStrategy, Portland General Electric And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
U.S. stock futures were lower this morning, with the Dow futures falling over 100 points on Thursday. 
Via Benzinga
Topics Stocks
News headline image
Why Zoomcar Shares Are Trading Higher By Around 142%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems Reports Third Quarter 2024 Results and Business Highlights
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems to Participate in Upcoming Investor Conferences
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems to Host Third Quarter 2024 Earnings Call
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems Announces Preliminary Third Quarter 2024 Revenue Results
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems Announces New Data Presented at ESMO 2024 Demonstrating Efficacy of HEPZATO KIT™ in Metastatic Uveal Melanoma Subgroups
From Delcath Systems, Inc.
Via Business Wire
News headline image
'This Is A Very Speculative Situation,' Jim Cramer On ADMA Biologics ↗
"Mad Money" host Jim Cramer said, "Any time there's immunity-compromised patients, there's some big money down the road." 
Via Benzinga
News headline image
Delcath Systems, Inc. Announces Positive Results from Independent Study on Liver-Directed Therapy for Uveal Melanoma Patients
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems, Inc. Announces Positive Outcomes from Independent Study on Hepatic Perfusion for Uveal Melanoma Patients
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems, Inc. Announces Promising Results from Independent Study on Repeated Hepatic Chemosaturation for Liver Tumors
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems Announces Poster Presentation at the 2024 ESMO Congress
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Delcath Systems, Inc.
Via Business Wire
News headline image
DCTH Stock Earnings: Delcath Systems Misses EPS, Beats Revenue for Q2 2024 ↗
DCTH stock results show that Delcath Systems missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Delcath Systems Reports Second Quarter 2024 Results and Business Highlights
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems Announces CMS Approval for NTAP for HEPZATO KIT™
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems to Participate in Upcoming Investor Conferences
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems to Host Second Quarter 2024 Earnings Call
From Delcath Systems, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.